Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Albuterol | 1 | 2018 | 212 | 0.590 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 499 | 0.520 |
Why?
|
| Alopecia | 2 | 2014 | 414 | 0.510 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 506 | 0.500 |
Why?
|
| Tinea Capitis | 3 | 2020 | 15 | 0.490 |
Why?
|
| Health Personnel | 4 | 2022 | 3310 | 0.470 |
Why?
|
| Telemedicine | 2 | 2022 | 3018 | 0.440 |
Why?
|
| Bronchiolitis | 1 | 2018 | 481 | 0.410 |
Why?
|
| Griseofulvin | 3 | 2020 | 10 | 0.400 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 1007 | 0.380 |
Why?
|
| Genes, Dominant | 1 | 2014 | 863 | 0.370 |
Why?
|
| Referral and Consultation | 2 | 2018 | 3598 | 0.300 |
Why?
|
| Cicatrix | 1 | 2014 | 782 | 0.300 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2754 | 0.290 |
Why?
|
| Medication Adherence | 1 | 2018 | 2165 | 0.280 |
Why?
|
| Antifungal Agents | 2 | 2020 | 749 | 0.240 |
Why?
|
| Rickets | 1 | 2005 | 71 | 0.240 |
Why?
|
| Durable Medical Equipment | 1 | 2023 | 23 | 0.230 |
Why?
|
| Primary Health Care | 1 | 2018 | 4647 | 0.190 |
Why?
|
| Lead Poisoning | 1 | 2023 | 321 | 0.180 |
Why?
|
| Desmoglein 1 | 1 | 2019 | 7 | 0.170 |
Why?
|
| Psychology, Social | 1 | 2018 | 52 | 0.160 |
Why?
|
| Wasting Syndrome | 1 | 2019 | 98 | 0.160 |
Why?
|
| Child | 15 | 2023 | 79806 | 0.160 |
Why?
|
| Connexin 43 | 1 | 2019 | 200 | 0.160 |
Why?
|
| Antimony Sodium Gluconate | 1 | 2018 | 11 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 17790 | 0.150 |
Why?
|
| Lead | 1 | 2023 | 880 | 0.150 |
Why?
|
| Leishmania | 1 | 2018 | 75 | 0.150 |
Why?
|
| Antiprotozoal Agents | 1 | 2018 | 94 | 0.150 |
Why?
|
| Dermatitis | 1 | 2019 | 200 | 0.150 |
Why?
|
| Israel | 4 | 2022 | 722 | 0.140 |
Why?
|
| Lasers, Gas | 1 | 2018 | 94 | 0.140 |
Why?
|
| Hemangioma, Capillary | 1 | 2017 | 62 | 0.140 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2018 | 136 | 0.130 |
Why?
|
| Office Visits | 1 | 2020 | 597 | 0.130 |
Why?
|
| Fee-for-Service Plans | 1 | 2020 | 705 | 0.130 |
Why?
|
| Propranolol | 1 | 2017 | 489 | 0.120 |
Why?
|
| Biopsy, Needle | 2 | 2014 | 1630 | 0.120 |
Why?
|
| Child, Preschool | 12 | 2023 | 42063 | 0.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2017 | 243 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2019 | 868 | 0.110 |
Why?
|
| Pediatrics | 2 | 2020 | 3586 | 0.110 |
Why?
|
| Infant | 9 | 2023 | 36060 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 7408 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 1416 | 0.100 |
Why?
|
| Vitamin D | 1 | 2005 | 3291 | 0.090 |
Why?
|
| Chromosome Disorders | 1 | 2014 | 499 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 1259 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3143 | 0.090 |
Why?
|
| Reimbursement, Incentive | 1 | 2015 | 542 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2019 | 1155 | 0.090 |
Why?
|
| Hemoglobinopathies | 1 | 2010 | 96 | 0.090 |
Why?
|
| Proteins | 1 | 2005 | 6029 | 0.090 |
Why?
|
| Busulfan | 1 | 2010 | 258 | 0.090 |
Why?
|
| Critical Care | 1 | 2022 | 2699 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2019 | 3448 | 0.080 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 1504 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2014 | 2295 | 0.080 |
Why?
|
| Retrospective Studies | 10 | 2023 | 80372 | 0.080 |
Why?
|
| Microsporum | 2 | 2019 | 7 | 0.080 |
Why?
|
| South Africa | 1 | 2014 | 1821 | 0.080 |
Why?
|
| Trichophyton | 2 | 2019 | 19 | 0.080 |
Why?
|
| Humans | 24 | 2023 | 760621 | 0.080 |
Why?
|
| Skin | 2 | 2019 | 4466 | 0.080 |
Why?
|
| Parents | 1 | 2022 | 3549 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2283 | 0.080 |
Why?
|
| Age Distribution | 1 | 2014 | 2893 | 0.070 |
Why?
|
| Refugees | 1 | 2016 | 598 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2018 | 2688 | 0.070 |
Why?
|
| Male | 18 | 2023 | 359744 | 0.070 |
Why?
|
| Ichthyosis, Lamellar | 1 | 2006 | 11 | 0.070 |
Why?
|
| Female | 18 | 2023 | 391270 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 1758 | 0.070 |
Why?
|
| Incidence | 4 | 2022 | 21392 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 11071 | 0.070 |
Why?
|
| Pedigree | 1 | 2014 | 4578 | 0.070 |
Why?
|
| State Government | 1 | 2009 | 380 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2018 | 3836 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 1824 | 0.060 |
Why?
|
| Medicare | 1 | 2023 | 6786 | 0.060 |
Why?
|
| Administration, Cutaneous | 2 | 2018 | 713 | 0.060 |
Why?
|
| Government Regulation | 1 | 2009 | 525 | 0.060 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 704 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2018 | 41335 | 0.060 |
Why?
|
| Age Factors | 2 | 2018 | 18416 | 0.060 |
Why?
|
| Sex Factors | 1 | 2018 | 10547 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2005 | 613 | 0.060 |
Why?
|
| HIV Protease Inhibitors | 1 | 2006 | 432 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2006 | 563 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 618 | 0.050 |
Why?
|
| Hospitalization | 1 | 2022 | 10790 | 0.050 |
Why?
|
| Adolescent | 7 | 2023 | 87810 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 13308 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 131 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5397 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 4291 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2006 | 4107 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 368 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2018 | 26181 | 0.040 |
Why?
|
| Gap Junctions | 1 | 2019 | 230 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 3025 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 566 | 0.040 |
Why?
|
| Neglected Diseases | 1 | 2018 | 66 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 1894 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 5799 | 0.040 |
Why?
|
| Laboratories | 1 | 2020 | 462 | 0.030 |
Why?
|
| Health Policy | 1 | 2009 | 2677 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2021 | 6068 | 0.030 |
Why?
|
| Gels | 1 | 2017 | 419 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2019 | 792 | 0.030 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2015 | 93 | 0.030 |
Why?
|
| Crowding | 1 | 2016 | 142 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2019 | 1199 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2009 | 4412 | 0.030 |
Why?
|
| Lysosomes | 1 | 2019 | 920 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1928 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 39261 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2019 | 539 | 0.030 |
Why?
|
| Hair | 1 | 2016 | 497 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2010 | 5649 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 24123 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2020 | 65017 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 58741 | 0.020 |
Why?
|
| Adult | 4 | 2022 | 219994 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2010 | 100 | 0.020 |
Why?
|
| Aged | 3 | 2023 | 169152 | 0.020 |
Why?
|
| Asthma | 1 | 2009 | 6172 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 822 | 0.020 |
Why?
|
| Medicaid | 1 | 2023 | 2815 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2015 | 664 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 4541 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 14660 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 25942 | 0.020 |
Why?
|
| Logistic Models | 1 | 2023 | 13314 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2010 | 565 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9287 | 0.020 |
Why?
|
| Middle Aged | 3 | 2022 | 220352 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2019 | 8313 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6771 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 12531 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2009 | 349 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 618 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 2262 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15620 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2005 | 12103 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2006 | 281 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2015 | 2963 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2006 | 388 | 0.010 |
Why?
|
| Poverty | 1 | 2016 | 2695 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8624 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2010 | 4035 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8803 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2006 | 1493 | 0.010 |
Why?
|
| Time Factors | 2 | 2018 | 40165 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 2388 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2015 | 4360 | 0.010 |
Why?
|
| United States | 2 | 2023 | 72461 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 2569 | 0.010 |
Why?
|
| Mutation | 2 | 2019 | 29932 | 0.010 |
Why?
|
| HIV Infections | 1 | 2006 | 17165 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3775 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4899 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54303 | 0.010 |
Why?
|
| Viral Load | 1 | 2006 | 3322 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 12960 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 22053 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 15789 | 0.000 |
Why?
|
Concepts
(168)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(32)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_